ArticleFrontiers in pharmacology2024

Overweight and glucose/lipid metabolism abnormality associated with SSRIs: a pharmacovigilance study based on the FDA adverse event reporting system.

Jinming Cao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.